Antimicrobials

Risk factors for antibiotic resistant bacterial colonisation in European Neonatal Units – results of the NeoIPC feasibility study

2025

Authors: Minotti C, Cook A, Berkell M, Bielicki J, on behalf of the NeoIPC Consortium.

Presented at: jENS Congress 2025

Transição precoce para Amoxicilina oral: seguro e eficaz em crianças hospitalizadas com Pneumonia Grave

2025

Presented by: Sidat M. M

Presented at: Jornadas Nacionais de Saude

Impacto da passagem oral à Amoxicilina ou Co-amoxiclav e da duração da terapêutica antibiótica na eficácia, segurança e selecção da resistência antibiótica na Pneumonia severa infantil adquirida na comunidade (PAC) – ensaio clínico PediCAP

2025

Presented by: Sidat M. M, em nome da equipe do ensaio PediCAP

Presented at: Simpósio Pré-Evento, XIII Conferência Científica da UEM

Pediatric stewardship in Italy: a necessity, not an option – a National Multi-Society Expert Consensus on Antimicrobial and Diagnostic Stewardship (SIP, SITIP, SIMRI, SIAIP, SIMEUP, SIPPS, SICUPP, SIMIT, SIMPE, SIPINF, SIT, SIAATIP, SARNEPI, AIEOP, SIM, SITI, SIF, SIFACT, SITA, SIN)

2025

Authors: Donà D, Barbieri E, Brigadoi G, Barchitta M, Berardi A, Bosis S, Buchini S, Buonsenso D, Cagliero A, Campana BR, Capello F, Carrozzo R, Castagnola E, Cazzato S,

Tolerability and Acceptability of Dispersible Oral Tablets of Amoxicillin and Co-Amoxiclav in African Children Hospitalized with Severe Pneumonia: Results from the PediCAP trial

2025

Presented by: Sidat MM, on behalf of the PediCAP trial team

Presented at: INSPiRED

Mortality and infection-related outcomes in low birth weight infants receiving Kangaroo Care: a systematic review and meta-analysis

2025

Authors: Minotti C, Jost K, Aghlmandi S, Schlaeppi C, Sieswerda E, Van Werkhoven H, Schulzke S, Bielicki J.

Presented at: ESPID 2025

View poster

All-cause mortality and infection-related outcomes of hospital-initiated kangaroo care versus conventional neonatal care for low-birthweight infants: a systematic review and meta-analysis

2025

Authors: Minotti C, Jost K, Aghlmandi S, Schlaeppi C, Sieswerda E, Van Werkhoven H, Schulzke S, Bielicki J.

Published in: The Lancet Child & Adolescent Health

Risk factors for resistant bacterial colonisation in 24 European neonatal units in the NeoIPC project

2025

Authors: Cook A, Berkell M, Malhotra-Kumar S, Bielicki J, on behalf of the NeoIPC Consortium.

Presented at: ESCMID 2025

View poster

A simulation study of antimicrobial resistance carriage in neonatal intensive care units: implications for cluster-randomised trials

2025

Authors: van Werkhoven CH, Berkell M, Cook A, Sieswerda E, Malhotra-Kumar S, Bielicki JA, by the NeoIPC consortium

Presented at: ESCMID 2025

View poster

Dynamics of gastrointestinal colonisation by antibiotic-resistant bacteria in high-risk infants in Swiss and Greek neonatal intensive care units

2025

Authors: Braspenning A, Timbermont L, Van Heirstraeten L, Berkell M, Cook A, Sieswerda E, van Werkhoven CH, Bielicki JA, Malhotra-Kumar S; on behalf of the NeoIPC Consortium.

Presented at: ESCMID 2025

View presentation

Pool-testing for surveillance of key bacterial resistance genes in infants’ stools

2025

Authors: Minotti C, Bräm D, Cook A, Berkell M, Bielicki J; and the NeoIPC Consortium

Presented at: ESCMID 2025

View poster

Investigating the implementation of infection prevention and control practices in neonatal care across country income levels: a systematic review

2025

Authors: Nyantakyi E, Baenziger J, Caci L, Blum K, Wolfensberger A, Dramowski A, Albers B, Castro M, Schultes MT, Clack L

Published in: Antimicrobial Resistance & Infection Control

Antibiotic resistant bacterial colonisation in 4 neonatal units in the UK: part of the NeoIPC Feasibility study

2024

Authors: Cook A, Martin J, Berkell M, Reid AE, Tanney K, Booth N, Clarke P, Roehr C, Bielicki J on behalf of the NeoIPC Consortium.

Presented at: Federation of Infection Societies Conference 2024 (FIS/HIS International)

View poster

Implementation determinants and strategies to infection prevention and control practices in neonatal care: Interim results of an exploratory network analysis

2024

Authors: Nyantakyi E, Schultes MT, Block P, Clack L.

Presented at: Conference of the Swiss Implementation Science Network (IMPACT) 2024

View poster

Early oral step-down to amoxicillin is safe and effective for children hospitalised with severe community-acquired pneumonia: the PediCAP trial

2024

Presented by: Musiime V on behalf of the PediCAP trial team

Presented at: 20th UPA Annual Scientific Conference 2024

View presentation slides

Impacto da passagem oral à Amoxicilina ou Co-amoxiclav e da duração da terapêutica antibiótica na eficácia, segurança e selecção da resistência antibiótica na Pneumonia severa infantil adquirida na comunidade (PAC) – ensaio clínico PediCAP

2024

Authors: Issa F, Sidat M, Joaquim W, Maieca A, Massitela C, Adriano Q, Cassia U, Martins S, Chilundo J, Manjate N, Macanze E, Sigaúque A, Chilengue R, Bombe M,

Antibiotic-resistant bacteria colonization patterns in different neonatal populations across European intensive care units (Poster)

2024

Authors: Minotti C, Bielicki J, on behalf of the NeoIPC Consortium.

Presented at: Joint Annual Meeting 2024 of the Swiss Society for Infectious Diseases (SSI),

View presentation

New amoxicillin-clavulanate dispersible tablets in children: a population pharmacokinetic analysis

2024

Authors: Dyk vJ on behalf of the PediCAP team

Presented at: PAGE 2024

Read more

Unit-level resistant colonisation in European neonatal intensive care units – Results from NeoIPC feasibility study

2024

Authors: Minotti C, Cook A, Martin J, Berkell M, Schlaeppi C, Bielicki J, on behalf of the NeoIPC Consortium

Presented at: ESPNIC 2024

View presentation

Antibiotic-resistant bacteria colonization patterns in different neonatal populations across European intensive care units (Presentation)

2024

Authors: Minotti C, Berkell M, Cook A, Martin J, Bielicki J, on behalf of the NeoIPC Consortium.

Presented at: ESPNIC 2024

View presentation

Reducing Neonatal Severe Infection and Resistance Through Optimised Skin-To-Skin Contact (KC – Kangaroo Care) Using Pragmatic Data Collection Approaches

2024

Authors: Djukic F, Aislinn A, Vitale E, Martin J, Minotti C, Schlaeppi C, Bielicki J.

Presented at: ESPID 2024

View presentation

Prevalence of antibiotic-resistant bacterial colonization in neonatal intensive care in Europe

2024

Authors: Berkell M, Van Heirstraeten L, Cook A, Bielicki J, Malhotra-Kumar S

Presented at: ESCMID Global (ECCMID) 2024

View poster

Unit-level antibiotic resistant bacterial colonisation pressure in 20 neonatal units across Europe

2024

Authors: Cook A, Berkell M, Bram D, on behalf of the NeoIPC Consortium

Presented at: ESCMID Global (ECCMID) 2024

View poster

Early oral step-down to amoxicillin is safe and effective for children hospitalised with severe community-acquired pneumonia: the PediCAP trial

2024

Authors: Musiime V on behalf of the PediCAP trial team

Presented at: ESCMID Global 2024

Read More

Navigating the COVID-19 Pandemic for Participant Recruitment and Follow-up: Experiences from the PediCAP Clinical Trial Consortium

2023

Authors: Kiggwe A, Nalwanga D, Tagoola A, Madhi S, Moore PD, Archary M, Mulenga V, Mujuru AH, Sacarlal J, Buck WC, Sidat M, Nguyen H, Haque F,

Read more

External factors affecting recruitment in a global paediatric pneumonia trial: lessons learned from PediCAP

2023

Authors: Pillay K, Archary M, Bielicki J, Buck WC, Clements M, Dennis E, Goelen J, Haque F, Kiggwe A, Madhi S, Moore PD, Mujuru AH,

Read more

Building a national network for inpatient pediatric clinical research in Mozambique 

2023

Authors: Sacarlal WJ, Buck C, Passanduca A, Macassa E, Saíde A, Chhaganlal K, Gafur M, Seni A, Machava S, Martins L, Issa F, Macanze E, Manjate N,

Read more

Receipt of intravenous co-amoxiclav challenged eligibility screening for the PediCAP Trial in Johannesburg, South Africa 

2023

Authors: Moore PD, Waggie Z, Nkosi S, Nkosi L, Kumalo N, Nkumana N, Zulu N, Dangor Z, Sharland M, Madhi S

Presented at: The EDCTP Forum 2023

Read more

Optimising kangaroo care to reduce neonatal severe infection/sepsis and resistant bacterial colonisation among high-risk infants in neonatal intensive care: a pragmatic, multicentre, parallel cluster randomised hybrid implementation–effectiveness trial (NeoDeco)

2023

Authors: Martin J, Cook A, Bielicki J, and the NeoIPC Consortium

Presented at: jENS Congress

View poster

O32 Using rapid qualitative inquiry for implementation support in a multinational study on infection prevention and control in neonatal intensive care

2023

Authors: Nyantakyi E, Schultes M-T, Bielicki J, Metsvaht T, Clack L & the NeoIPC consortium

Published in: Proceedings of the 5th UK Implementation Science Research Conference,

Kangaroo care as a potential infection prevention and control (IPC) measure in neonatal intensive care units

2023

Authors: Schlaeppi C, Bielicki J, and the NeoIPC Consortium.

Presented at: ESPID 2023

View poster

Descriptive interim analysis of the sampling strategy in anonymous repeated cross-sectional samples in European neonatal intensive care units (NICU)

2023

Authors: Golhen K, Gotta V, Pfister M, Bielicki J.

Presented at: ESPID 2023

View poster

Infection prevention and control practices in neonatal units participating in the NeoIPC project

2023

Authors: Schlaeppi C, Bielicki J, and the NeoIPC Consortium

Presented at: ECCMID 2023

View poster

Antibiotic use in neonatal care: measuring cumulative exposure in point prevalence surveys identifies high infant-level antibiotic exposure

2023

Authors: Cook A, Bielicki J, and the NeoIPC Consortium

Presented at: ECCMID 2023

View poster

Implementation of infection prevention and control for hospitalised neonates: A narrative review

2022

Authors: Nyantakyi E, Caci L, Castro M, Schlaeppi C, Cook A, Albers B, Walder J, Metsvaht T, Bielicki J, Dramowski A, Schultes MT, Clack L

Published in: Clinical Microbiology and Infection

Antibiotics needed to treat multidrug-resistant infections in neonates

2022

Authors: CM Williams PCM, Qazi SA, Agarwal R, Velaphi S, Bielicki JA, Nambiar S, Giaquinto C, Bradley J, Noel GJ, Ellis S, O’Brien S, Balasegaram M & Sharland M

Published in: Bulletin of the World Health Organization

Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial

2021

Authors: Hill L.F, Clements M.N, Turner M.A, Donà D, Lutsar I, Jacqz-Aigrain E, Heath P.T, Roilides E, Rawcliffe L, Alonso-Diaz C, Baraldi E, Dotta A, Ilmoja M, Mahaveer A,

Global estimates of the relative pediatric consumption and cost of oral amoxicillin and amoxicillin plus clavulanic acid

2021

Authors: G. A. Levine, M. Sharland, S. Ellis, Y. Ferrisse, C. Loze, Y. Hsia, G. Fink, J. Bielicki; for the PediCAP project

Presented at: ECCMID 2021

View e-poster

Harmonising regulatory approval for antibiotics in children

2021

Authors: Phoebe C M Williams, John Bradley, Emmanuel Roilides, Linus Olson, Sheldon Kaplan, Irja Lutsar, Carlo Giaquinto, Daniel K Benjamin, Mike Sharland

Published in: The Lancet

Global sales of oral antibiotics formulated for children

2020

Authors: Li G, Jackson C, Bielicki J, Ellis S, Hsiac Y, Sharland M

Published in: Bulletin of the World Health Organization,

A comparison of five paediatric dosing guidelines for antibiotics

2020

Authors: Mathur S, Jackson C, Urus H, Ziarko I, Goodbun M, Hsia Y, Ellis S, Sharland M.

Published in: Bulletin of the World Health Organization,

Interim pharmacokinetic analysis of a multi-centre randomised open label phase IIb study in neonates to validate the meta-analysis population pharmacokinetic model used to simulate an optimised dosing regimen in neonates and infants aged < 90 days: the NeoVanc trial

2020

Authors: L. Hill, E. Jacqz-Aigrain, V. Elie, W. Zhao, M. Clements, M. Turner, I. Lutsar, P. Heath, E. Roilides, S. Walker, M. Sharland

Published in: 30th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID),

Read More

An optimised dosing regimen vs. a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in infants less than 90 days: the NeoVanc trial

2020

Authors: L. Hill, M. Clements, M. Turner, I. Lutsar, E. Jacqz-Aigrain, P. Heath, E. Roilides, S. Walker, M. Sharland

Published in: 30th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID),

Application of WISCA (Weighted Incidence Syndromic Combination Antibiogram) to guide empiric therapy in oncological paediatric patients with febrile neutropenia

2020

Authors: E. Barbieri, D. Bottigliengo, P. Costenaro, A. Marzollo, M. Petris, M. Pierobon, G. Biddeci, C. Giaquinto, A. Biffi, D. Donà

Published in: 30th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID),

Antibiotic treatment for paediatric outpatients with community-acquired pneumonia: findings from 10 years of prescribing habits in Italy

2020

Authors: P. Costenaro, A. Cantarutti, E. Barbieri, A. Scamarcia, A. Oletto, P. Sacerdoti, R. Lundin, L. Cantarutti, C. Giaquinto, D. Dona’

Published in: 30th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID),

An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial

2020

Authors: Hill LF, Turner MA, Lutsar I, et al; NeoVanc Consortium.

Published in: Trials. 2020;21(1):329

Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review

2020

Authors: Donà D, Barbieri E, Daverio M, Lundin R, Giaquinto C, Zaoutis T, Sharland M

Published in: Antimicrob Resist Infect Control.2020;9:3

Background Antibiotics are the most common medicines prescribed to children in hospitals and the community,

Standardising neonatal and pediatric anitibiotic clinical trial design and conduct: the PENTA-ID network review

2019

Authors: Folgori L, Lutsar I, Standing JF, et al.

Published in: BMJ Open. 2019; 9:e032592

Abstract: Antimicrobial development for children remains challenging due to multiple barriers to conducting randomised clinical trials (CTs).

Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network

2019

Authors: Li G, Bielicki JA, Ahmed ASMNU, et al.

Published in: Arch Dis Child.2091;0:1-6

Objective To gain an understanding of the variation in available resources and clinical practices between neonatal units (NNUs) in the low-income and middleincome country (LMIC) setting to inform the design of an observational study on the burden of unit-level antimicrobial resistance (AMR).

Differential susceptibility of Staphylococcus epidermidis biofilms to vancomycin, daptomycin and linezolid between clinical Isolates from neonates and adults

2019

Authors:Simitsopoulou M, Kadiltzoglou P, Kyrpitzi D, Roilides E.

Published in: Int J Biol Med Res.2019;10(1):6591-6596

Abstract This study aimed to compare the effects of vancomycin,

12